Articles related to IMMUNOTHERAPY

In light of recent findings, CD24Fc emerges as a potential game-changer in preventing acute GVHD in HSCT patients, with a notable survival rate improvement to 96.2% for severe cases.

In the landmark KEYNOTE-564 trial, pembrolizumab has emerged as a pivotal advancement in kidney cancer treatment, offering hope by significantly prolonging survival in patients with high-risk ccRCC post-nephrectomy.

Physicians should be acutely aware of the heightened risk of neuroinvasive arboviral infections in patients treated with rituximab, necessitating a shift towards molecular diagnostic testing for timely and accurate detection.

Recent studies have highlighted the effectiveness of ruxolitinib in managing steroid-refractory chronic graft-vs-host disease, showcasing a significant improvement in overall response rates and failure-free survival compared to standard therapies.

Recent advances in CAR T-cell therapy show significant promise in treating both blood cancers and solid tumors, offering durable responses and extended survival rates for patients previously facing limited options.

ESMO Congress 2023 unveils groundbreaking advances in mUC treatments, emphasizing novel therapeutic combinations and the critical role of personalized medicine in improving patient outcomes.